Equities analysts expect that Travere Therapeutics, Inc. (NASDAQ:TVTX) will post $50.20 million in sales for the current quarter, according to Zacks. Four analysts have provided estimates for Travere Therapeutics’ earnings. The highest sales estimate is $50.42 million and the lowest is $50.00 million. Travere Therapeutics reported sales of $48.43 million during the same quarter last year, which indicates a positive year-over-year growth rate of 3.7%. The firm is scheduled to issue its next earnings report on Thursday, July 29th.
On average, analysts expect that Travere Therapeutics will report full-year sales of $199.71 million for the current financial year, with estimates ranging from $192.60 million to $207.60 million. For the next fiscal year, analysts expect that the firm will report sales of $200.34 million, with estimates ranging from $186.13 million to $216.80 million. Zacks’ sales calculations are an average based on a survey of sell-side analysts that that provide coverage for Travere Therapeutics.
Travere Therapeutics (NASDAQ:TVTX) last issued its quarterly earnings results on Thursday, May 6th. The company reported ($0.96) EPS for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.40). The company had revenue of $47.41 million during the quarter, compared to analysts’ expectations of $49.99 million. Travere Therapeutics had a negative return on equity of 75.08% and a negative net margin of 113.21%.
In related news, CEO Eric M. Dube sold 9,562 shares of the firm’s stock in a transaction that occurred on Wednesday, June 2nd. The stock was sold at an average price of $14.62, for a total transaction of $139,796.44. 4.31% of the stock is currently owned by company insiders.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in TVTX. Janus Henderson Group PLC purchased a new position in Travere Therapeutics during the 4th quarter worth $111,297,000. Armistice Capital LLC purchased a new position in shares of Travere Therapeutics in the 1st quarter valued at $58,829,000. Avoro Capital Advisors LLC purchased a new position in shares of Travere Therapeutics in the 4th quarter valued at $49,073,000. Oak Ridge Investments LLC increased its holdings in shares of Travere Therapeutics by 983.9% in the 1st quarter. Oak Ridge Investments LLC now owns 1,323,149 shares of the company’s stock valued at $33,039,000 after acquiring an additional 1,201,073 shares during the period. Finally, Dimensional Fund Advisors LP purchased a new position in shares of Travere Therapeutics in the 4th quarter valued at $32,481,000.
Shares of NASDAQ:TVTX traded down $0.34 during trading on Monday, hitting $13.40. 10,426 shares of the company’s stock were exchanged, compared to its average volume of 703,376. The company has a debt-to-equity ratio of 0.60, a quick ratio of 6.56 and a current ratio of 6.65. Travere Therapeutics has a 52-week low of $13.24 and a 52-week high of $33.09. The firm has a 50-day moving average of $15.42. The firm has a market capitalization of $810.16 million, a P/E ratio of -3.16 and a beta of 0.67.
About Travere Therapeutics
Travere Therapeutics, Inc, a biopharmaceutical company, focuses on the identification, development, and commercialization of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola and Thiola EC, a tiopronin tablet for the treatment of homozygous cystinuria.
Further Reading: What is the Bid-Ask Spread?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Travere Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Travere Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.